Abstract Context The European Association of Urology (EAU) has released an updated
version of the guidelines on non–muscle-invasive bladder cancer (NMIBC). Objective To …

Context This overview presents the updated European Association of Urology (EAU)
guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ …

Aim This narrative review aims to describe established and emerging urinary biomarkers in
the diagnosis and surveillance of non-muscle invasive bladder cancer. It provides a …

Context During the past decade, several urinary biomarker tests (UBTs) for bladder cancer
have been developed and made commercially available. However, none of these is …

Bladder cancer (BC) ranks as the sixth most prevalent cancer in the world, with a steady rise
in its incidence and prevalence, and is accompanied by a high morbidity and mortality. BC is …

Bladder cancer (BC) is characterized by high incidence and recurrence rates together with
genomic instability and elevated mutation degree. Currently, cystoscopy combined with …

Currently available point-of-care tests for Bladder Cancer (BC) are qualitative and prone to
high false positives, thus preventing them from replacing clinical cystoscopy as reliable …

Bladder cancer is one of the most financially burdensome cancers globally, from its
diagnostic to its terminal stages. The impact it imposes on patients and the medical …

Bladder cancer (BC) is ones of the most common cancer worldwide. It is classified in muscle
invasive (MIBC) and muscle non-invasive (NMIBC) BC. NMIBCs frequently recur and …

Extracellular vesicles (EVs) are small membrane vesicles released by all cells and involved
in intercellular communication. Importantly, EVs cargo includes nucleic acids, lipids, and …